MissionIR Articles

FluoroPharma, a developer of imaging agents used in association with positron emission tomography (PET) scanning, was founded in 2003 by Dr. David Elmaleh, currently the company’s Chief Scientific Officer, who has gathered around him some…

The use of PET scans (positron emission tomography) for identifying and evaluating cancer is well-known. Most of the millions of PET procedures currently performed in the U.S. every year relate to cancer diagnosis. But developers…

FluoroPharma Medical, based in Boston, is a developer of imaging agents for use with positron emission tomography (PET). PET is a nuclear medicine imaging technology able to make visible very subtle events occurring deep within…

In March, when FluoroPharma Medical, a developer of unique imaging agents for use with positron emission tomography (PET), filed their 10-K for fiscal 2011, there were no surprises, leading Zack’s Investment Research to reaffirm its…

Approximately 1 out of 8 older Americans has Alzheimer’s disease. It is the most common form of dementia, and the sixth leading cause of death in the U.S. In spite of extensive research and public…

Today, shortly after the opening bell, FluoroPharma Medical announced that BFPET, its imaging agent for measuring cardiovascular blood flow, has been granted patent rights in Australia. BFPET is a novel cardiovascular blood flow imaging agent…

Cardiovascular disease (CVD), also referred to as coronary artery disease (CAD), has been on top of the world’s illness list for a long time, and yet it’s still surprising to consider that fully one-third of…

Medical researchers are today coming up with new understandings of the molecular processes that cause disease to a degree never before possible. Alzheimer’s, cancer, and heart disease, among many others, are now being studied at…

FluoroPharma Medical, a biopharmaceutical company engaged in the development of breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology to detect and assess pathology before clinical manifestation of diseases, just announced that the…

The positive report just released by Zacks Small-Cap Research on FluoroPharma Medical, developer of advanced medical diagnostic imaging tracer products for use with positron emission tomography (PET), highlights the principal advantages of FluoroPharma in the…

FluoroPharma Medical, Inc. is a company seeking to develop breakthrough molecular imaging agents for the PET (positron emission tomography) type of 3D medical imaging of the human body to meet critical medical needs. The company…

Turning a good idea into a money making product can be a formidably expensive project, especially when dealing with medical substances to be introduced to the human body. FluoroPharma, developer of medical diagnostic imaging agents…

For many emerging companies, the ideal exit is a big-money major-corporate buyout, giving principals and investors a whopping return. Unfortunately, it’s not the most common outcome. Getting the right mix of technology, application, market demand,…

When FluoroPharma CEO, Thijs Spoor, recently gave a presentation summarizing the rising importance in medical diagnostics of PET technology, and the associated radiopharmaceuticals such as those developed by FluoroPharma, it brought into focus a major…

It’s almost impossible to overstate the significance of medical imaging in the development of modern medicine. The New England Journal of Medicine, considered the world’s oldest and single most influential general medical periodical, calls medical…

FluoroPharma Medical, a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products, announced that its president and CEO, Thijs Spoor, will be presenting at Noble Financial Capital Markets’ Eight Annual Equity…

In medicine, there’s no more important organ than the heart, the pump that circulates oxygen carrying blood throughout the body, keeping every cell alive. When circulation stops, so does life. The single biggest cause of…

Fluoropharma Medical, developer of advanced medical diagnostic imaging products, sees an open-ended range of potential markets in its future, since many of the possibilities related to the advanced imaging technologies on which the company is…

FluoroPharma Medical, a biopharmaceutical company providing proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels, announced that it has appointed Lawrence Atinsky to its Board of Directors. The appointment is…